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a b s t r a c t
Endogenous estrogen plays an integral role in the etiology of breast and endometrial cancer, and conceivably ovarian cancer. However, the underlying mechanisms and the importance of patterns of estrogen
metabolism and speciﬁc estrogen metabolites have not been adequately explored. Long-standing
hypotheses, derived from laboratory experiments, have not been tested in epidemiologic research
because of the lack of robust, rapid, accurate measurement techniques appropriate for large-scale studies. We have developed a stable isotope dilution liquid chromatography–tandem mass spectrometry
(LC–MS2 ) method that can measure concurrently all 15 estrogens and estrogen metabolites (EM) in urine
and serum with high sensitivity (level of detection = 2.5–3.0 fmol EM/mL serum), speciﬁcity, accuracy, and
precision [laboratory coefﬁcients of variation (CV’s) ≤5% for nearly all EM]. The assay requires only extraction, a single chemical derivatization, and less than 0.5 mL of serum or urine. By incorporating enzymatic
hydrolysis, the assay measures total (glucuronidated + sulfated + unconjugated) EM. If the hydrolysis step
is omitted, the assay measures unconjugated EM. Interindividual differences in urinary EM concentrations
(pg/mL creatinine), which reﬂect total EM production, were consistently large, with a range of 10–100fold for nearly all EM in premenopausal and postmenopausal women and men. Correlational analyses
indicated that urinary estrone and estradiol, the most commonly measured EM, do not accurately represent levels of total urinary EM or of the other EM. In serum, all 15 EM were detected as conjugates,
but only 5 were detected in unconjugated form. When we compared our assay methods with indirect
radioimmunoassays for estrone, estradiol, and estriol and enzyme-linked immunosorbent assays for 2hydroxyestrone and 16␣-hydroxyestrone, ranking of individuals agreed well for premenopausal women
[Spearman r (rs ) = 0.8–0.9], but only moderately for postmenopausal women (rs = 0.4–0.8). Our absolute
readings were consistently lower, especially at the low concentrations characteristic of postmenopausal
women, possibly because of improved speciﬁcity. We are currently applying our EM measurement techniques in several epidemiologic studies of premenopausal and postmenopausal breast cancer.
Published by Elsevier Ltd.
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1. Endogenous estrogen and breast, endometrial, and
ovarian cancer

cers, the mechanisms of estrogen-mediated carcinogenesis have
yet to be deﬁned, and may differ among the three sites.

In the last decade, the evidence that endogenous estrogen levels
are causally related to breast cancer has strengthened substantially. In 2002, a pooled analysis of the worldwide data from
prospective studies, which included 663 women who developed
breast cancer and 1765 women who did not, demonstrated that
risk of postmenopausal breast cancer increased signiﬁcantly (p
for trend <0.001) with increasing circulating concentrations of
estrone sulfate, estrone, and estradiol [1]. For each estrogen, risk
doubled between extreme quintiles. Urinary concentrations of
estrogens have also been positively associated with subsequent
risk of postmenopausal breast cancer, with trends in risk reaching statistical signiﬁcance [2,3]. However, prospective studies have
not yet conclusively shown an association between circulating or
urinary estrogens and risk of premenopausal breast cancer, quite
possibly because of the complexity of controlling for variation
in estrogen levels during the menstrual cycle [3,4]. Fewer data
exist for endometrial cancer. In the largest prospective study to
date, including 247 incident cases of endometrial cancer and 481
controls from the European Prospective Investigation into Cancer
and Nutrition (EPIC), risk of endometrial cancer increased signiﬁcantly with serum concentrations of estrone and estradiol in
postmenopausal women (p for trend <0.01), but was not clearly
related in premenopausal women [5]. Among postmenopausal
women, associations with endometrial cancer seemed stronger
than those with breast cancer, with relative risks reaching 2.7 when
extreme tertiles of estrone were compared. Only a few small studies of ovarian cancer have been published, and associations with
endogenous estrogen have been inconsistent [6]. For all three can-

2. Estrogen metabolism and cancer
Although experimental, clinical, and epidemiologic research
have implicated endogenous estrogens in the etiology of breast
and endometrial cancer, and possibly ovarian cancer, the role
of individual patterns of estrogen metabolism has been largely
unexplored in epidemiologic work [7]. Metabolism of estrogens occurs in the liver and kidneys, and in target tissues, and
includes oxidative metabolism (hydroxylation) and conjugative
metabolism (methylation, sulfation, and/or glucuronidation) [8].
Oxidation of the parent estrogens, estrone and estradiol, occurs
at either the 2-, 4- or 16-position of the carbon skeleton to yield
2-hydroxylated, 4-hydroxylated, or 16-hydroxylated estrogens,
respectively (Fig. 1) [9]. At least 15 human cytochrome P450 isoforms, phase I enzymes that vary in their distribution across target
tissues, their catalytic activity, and their speciﬁcity, are capable
of catalyzing these hydroxylations [10]. Catechol estrogens, with
adjacent hydroxyl groups at the 2- and 3-positions or the 3and 4-positions, can be methylated (Fig. 1), which is generally
considered an excretory pathway [11]. 16␣-hydroxyestrone can
be further metabolized by reduction and oxidation at the 17and 16-positions (Fig. 1). Conjugation with sulfate or glucuronide
moieties is known to modulate the bioavailability of estrogens
and estrogen metabolites (which we refer to jointly as EM).
Sulfation of estrogens may extend the half-life in circulation while
glucuronidation is an important excretory pathway for estrogens.
Estrogen metabolism yields products that are potentially both
estrogenic and genotoxic. Speciﬁc estrogen metabolism pathways,

Fig. 1. The estrogen metabolites formed by hydroxylation of the parent estrogens, estrone and estradiol, at the 2-, 4-, or 16-positions of the carbon ring. The relative size of
the chemical structures indicates the relative concentration in urine in premenopausal women, postmenopausal women, and men [18].
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such as formation of the 16-hydroxylated estrogens with their
strong hormonal and mitogenic activity, are postulated to increase
breast cancer risk [12]. Alternatively, speciﬁc estrogen metabolites,
such as the reactive catechol estrogens, may function as carcinogens by reacting with DNA to form stable or depurinating adducts
[7] although it has also been postulated that 2-pathway catechol
estrogens may actually be protective since their formation precludes 16-hydroxylation [13]. The 4-pathway catechol estrogens,
though substantially less abundant, are potent inducers of DNA
damage in animal and in vitro models and have been hypothesized to increase breast cancer risk [14]. Methylation of catechol
estrogens weakens binding to the estrogen receptor, thus reducing estrogenicity, and prevents reactive quinone formation; both
effects should reduce cancer risk [11]. Estrogen metabolism patterns may also determine how bioavailable estrogen is in target
tissue and how efﬁciently it is removed from circulation.
3. Liquid chromatography–tandem mass spectrometry
(LC–MS2 ) assay for estrogens and estrogen metabolites (EM)
Nine years ago, we decided to attempt a “high risk/high reward”
project. The laborious “gold standard” mass spectrometry methods
for measuring endogenous steroid hormones were being abandoned, and the limitations of commercial radioimmunoassay (RIA),
enzyme immunoassay (EIA), and enzyme-linked immunoassay
(ELISA) kits were complicating epidemiologic research on hormonal carcinogenesis. Variability over time, between kits, and
among labs frustrated individual and pooled analyses. Each hormone was assayed independently, and required 0.2–1.0 mL and
substantial costs per sample. In addition, long-standing hypotheses
about the importance of individual steroid hormone metabolites and patterns of metabolism, based on experimental research,
were not being evaluated in epidemiologic studies. Robust, relatively rapid analytic methods capable of characterizing estrogen
metabolism in the large number of biologic samples collected in
epidemiologic research were required.
In a multidisciplinary effort, Drs. Larry Keefer, Tim Veenstra, Xia
Xu, and Regina Ziegler have collaborated to develop an accurate,
precise, and sensitive high-performance liquid chromatographyelectrospray ionization-tandem mass spectrometry method for
measuring concurrently the endogenous EM in human serum and
urine [15,16]. The procedure is relatively simple and rapid; it
requires hydrolysis, extraction, and a single chemical derivatization, and only 0.5 mL of serum or urine (Fig. 2). Enzymatic hydrolysis
with Helix pomatia extract removes sulfate and glucuronide

Fig. 2. Schematic of liquid chromatography–tandem mass spectrometry procedure
for measuring endogenous estrogens and estrogen metabolites (EM) in serum and
urine samples. Total (conjugated and unconjugated) EM are measured by including
the enzymatic hydrolysis step. Only unconjugated EM are measured if the hydrolysis
step is omitted. The chemical structure for dansylated estradiol indicates how the
1-dimethylamino-naphthalene-5-sulfonyl (dansyl) moiety covalently binds to the
phenolic hydroxyl at the 3-position, a deﬁning characteristic of all EM.

residues from the EM. Omitting the hydrolysis step enables
us to measure the quantities of unconjugated EM. The single
derivatization adds a bulky, charged dansyl (1-dimethylaminonaphthalene-5-sulfonyl) group to the phenolic hydroxyl at the
3-position on each EM. This reactive hydroxyl, characteristic of all
estrogens, enables our technique to measure not only the parent
estrogens but also all the estrogen metabolites. The dansylation
is critical since mass spectrometry separates and detects compounds on the basis of charge and molecular weight, and does not
perform efﬁciently with neutral, fat-soluble compounds, such as
steroids. Electrospray ionization is utilized to gently convert complex biological solutions into gas phase ions and link the liquid
chromatography to the mass spectrometer. In order to identify
unique, well-resolved peaks for each EM, many of which are chemically very similar, we incorporate tandem mass spectrometry, in
which a second fragmentation and separation is applied to the ions
generated by the initial fragmentation. Finally, a deﬁning characteristic of our approach is reliance on stable isotope dilution. We
add stable 2 H- or 13 C-labeled EM standards at the beginning, before
hydrolysis, so that we can quantitatively correct for loss or degradation during all steps of the procedure.
With our LC–MS2 technique, we can simultaneously measure
the absolute quantities of the two parent EM, estrone and estradiol; the two catechol and three methylated catechol EM in the
2-hydroxylation pathway (2-hydroxyestrone, 2-hydroxyestradiol
and 2-methoxyestrone, 2-methoxyestradiol, 2-hydroxyestrone-3methyl ether); the one catechol and two methylated catechol
EM in the 4-hydroxylation pathway (4-hydroxyestrone and
4-methoxyestrone, 4-methoxyestradiol); and the ﬁve EM in
the 16-hydroxylation pathway (16␣-hydroxyestrone, estriol, 17epiestriol, 16-ketoestradiol, 16-epiestriol) (Fig. 1).
Mass spectrometry techniques are increasingly viewed as the
most promising approach for improving sensitivity, speciﬁcity,
accuracy, and precision in steroid hormone measurement, and the
“gold standard” against which traditional RIA, EIA, and ELISA should
be compared [17]. Our LC–MS2 assays for EM in serum and urine
offer the advantages of mass spectrometry and, in addition, analyse
parent estrogens and a wide variety of their metabolites in a single
run.

4. EM in urine
In 2005, we published our LC–MS2 technique for the simultaneous measurement of the absolute quantities of 15 urinary EM,
which are presented in Fig. 1 [16]. Because EM are mostly present
in urine as glucuronide or sulfate conjugates, we are currently
measuring total EM, the sum of the glucuronidated, sulfated, and
unconjugated forms of each EM. The conjugated EM within each
urine sample are enzymatically hydrolyzed after addition of the
isotopically labelled standards. We start with 0.5 mL of urine, and
10% is eventually placed on the column. The lower level of quantitation for each EM is 40 pg/mL urine (∼150 fmol/mL). The level
of quantitation is the concentration at which we know we have
acceptably low coefﬁcients of variation (CV’s) because of sufﬁciently high signal-to-noise ratios. Our level of detection, which
is the “sensitivity” reported in the literature for most steroid hormone assays, is ∼4 pg/mL urine (∼15 fmol/mL). Accuracy, based on
percent recovery of a known amount of unconjugated EM added to
charcoal-stripped human urine, is 96–107%. Calibration curves are
linear over a 103 -fold concentration range. At this point in time, we
are relying on ﬁve stable isotopically labeled standards for the 15
EM: deuterated estradiol, 2-hydroxyestradiol, 2-methoxyestradiol,
estriol, and 16-epiestriol.
Using overnight urines from ﬁve follicular phase and ﬁve luteal
phase premenopausal women, ﬁve postmenopausal women, and
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ﬁve men, we conducted a formal “proof of performance” of our
urinary EM assay by measuring two randomized, blinded aliquots
from each subject in each of four batches over four weeks [18]. None
of the women were currently using exogenous hormones, such as
oral contraceptives or menopausal hormone therapy. Laboratory
CV’s, which included the hydrolysis, extraction, and derivatization
steps as well as within and between batch variation, were ≤10% for
each of the 15 EM, and generally ≤5%. Intraclass correlation coefﬁcients (ICC’s) within each menstrual/sex group, a measure of the
variability attributable to interindividual differences, were generally ≥0.98. Thus, within each menstrual/sex group, the range in
concentration of each EM was quite large relative to assay variability. The ICC’s may be somewhat imprecise because of the small
number of participants in the study but were remarkably consistent
across the four menstrual/sex groups.
For descriptive analyses, we combined data from an additional 25 subjects with the data from these 20 subjects [18].
Although geometric mean EM concentrations (pg EM/mg creatinine) differed substantially among the four menstrual/sex groups,
the rankings of the individual EM were quite similar, with
estriol, 2-hydroxyestrone, estrone, estradiol, and 16-ketoestradiol
accounting for 60–75% of total urinary EM. The three catechol estrogens comprised 20–25% of total EM, while the ﬁve methylated
catechol estrogens were 5–10%. What was especially exciting was
that within each menstrual/sex group, interindividual differences
in urinary EM concentrations, which reﬂect interindividual differ-
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ences in EM production and excretion, were consistently large, with
a range of 10–100-fold for nearly all EM. This interindividual variation is highlighted in Fig. 3, which shows box plots of urinary
concentrations of the three catechol EM, the ﬁve methylated catechol EM, and the ﬁve 16-pathway EM for each menstrual/sex group.
EM concentration is plotted on a logarithmic scale, with a different
scale for each boxplot.
At this point, we knew that interindividual variability in urinary EM concentrations was substantially larger than laboratory
variation. However, we did not know whether variation in urinary EM levels in an individual over secular time would limit our
ability to identify associations with risk when we relied upon a
single urine collection, as is typical of most epidemiologic studies. Dr. Sue Hankinson at Harvard School of Public Health had
collected urine samples in the Nurses’ Health Study II cohort
that were appropriate for addressing this question. With Dr.
Heather Eliassen, also at Harvard, we examined the reproducibility of urinary EM concentrations in 110 premenopausal women
with luteal phase urine samples collected during each of three
years [19]. On average, parent EM (estrone and estradiol) were
21% (5th–95th percentiles = 12–34%) of total urinary EM and 2pathway, 4-pathway, and 16-pathway EM were 36% (12–62%), 4%
(1–8%), and 39% (17–67%), respectively; interindividual variation in
estrogen metabolism was clearly apparent. Reproducibility within
a woman over time was relatively high for the three hydroxylation
pathways, with ICC’s ranging from 0.52 (16-pathway EM) to 0.57

Fig. 3. Interindividual variation in urinary concentrations of catechol estrogens and estrogen metabolites (EM), methylated catechol EM, and 16-pathway EM is shown
with box plots for 10 premenopausal follicular phase women, 10 premenopausal luteal phase women, 15 postmenopausal women, and 10 men. Urinary EM concentrations
are in pg/mg creatinine and presented on a logarithmic scale. The ﬁrst graph summarizes interindividual variation of the catechol EM, shown in the following order: 2hydroxyestrone (2-OHE1 ), 2-hydroxyestradiol (2-OHE2 ), and 4-hydroxyestrone (4-OHE1 ). The second graph summarizes interindividual variation of the methylated catechol
EM: 2-methoxyestrone (2-MeOE1 ), 2-methoxyestradiol (2-MeOE2 ), 2-hydroxyestrone-3-methyl ether (3-MeOE1 ), 4-methoxyestrone (4-MeOE1 ), and 4-methoxyestradiol (4MeOE2 ). The third graph summarizes interindividual variation of the 16-pathway EM: 16␣-hydroxyestrone (16␣-OHE1 ), 17-epiestriol (17-epiE3 ), estriol (E3 ), 16-ketoestradiol
(16-ketoE2 ), and 16-epiestriol (16-epiE3 ). The horizontal line within each box is the median of the distribution. The top and bottom of each box are the interquartile range
(75 and 25 percentiles, respectively) of the distribution. The vertical lines above and below each box extend to the extreme values that are not outliers (≤1.5 times the
interquartile range). Outliers are represented as stars (>1.5 but ≤3 times the interquartile range) and open circles (>3 times the interquartile range).
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(4-pathway EM) to 0.72 (2-pathway EM), which were as high as
or higher than the ICC’s for estrone and estradiol (∼0.5). ICC’s for
the individual catechol EM and 2-pathway methylated catechol EM
were comparably high. Because of their low concentrations, ICC’s
for the individual methylated catechol EM in the 4-pathway were
relatively low (<0.3). Converting absolute EM concentrations (pmol
EM/mg creatinine) to relative concentrations (pmol EM expressed
as percent of total EM in pmol) noticeably improved the ICC’s.
These data indicate that urinary EM levels do vary substantially
among individuals when compared to intraindividual variability.
It is encouraging that reproducibility in premenopausal women
over time for most individual and grouped EM is comparable to
or better than that of well-vetted biomarkers, such as circulating
cholesterol (ICC = 0.65); blood glucose (ICC = 0.52); and, in postmenopausal women, plasma estradiol (ICC = 0.68), all of which are
considered to be reliable predictors of disease in epidemiologic
studies [19].
We also evaluated Spearman correlations among the EM [19].
Urinary estrone was only moderately correlated with the individual estrogen metabolites (most rs = 0.3–0.6), while correlations
between urinary estradiol and the individual metabolites were still
lower (rs = 0.1–0.4). However, individual EM within a pathway were
fairly highly correlated. The 2-pathway EM and 4-pathway EM
were highly correlated (rs = 0.9), but both pathways were weakly
and inversely correlated with the 16-pathway EM (rs = −0.2). These
data suggest that urinary concentrations of the parent EM, estrone
and estradiol, do not accurately represent the concentrations of
individual estrogen metabolites. Potentially important additional
information is obtained when the entire estrogen metabolism proﬁle is measured in urine.
In preparation for large-scale epidemiologic studies, we have
studied the stability of the 15 EM in urine samples, with and without added ascorbic acid (0.1% w/v), during (1) interim storage at
4 ◦ C, (2) long-term storage at −80 ◦ C, and (3) freeze-thaw cycles
[20]. Early morning urine specimens were provided by three premenopausal women. We saw no consistent evidence of >1% loss for
any of the EM during interim storage for 24 h, long-term storage for
one year, or two additional freeze-thaw cycles in the samples without added ascorbic acid. Given the large interindividual variability
in urinary EM concentrations we have observed [18], these changes
are unlikely to cause substantial misclassiﬁcation in epidemiologic
research. To our surprise, ascorbic acid, an antioxidant which has
been suggested in the literature as necessary to protect speciﬁc EM
[21,22], had no clear beneﬁcial effects on individual EM stability in
any of these experiments. Therefore, for epidemiologic and clinical studies that will be collecting urine samples in which EM will
be measured, we suggest immediately chilling the urine sample to
4 ◦ C on collection, or the individual portions of urine if a 12- or 24 h
collection is planned; keeping the urine at 4 ◦ C for no more than
1–2 days before decanting and aliquotting for long-term storage at
−70 ◦ C; and adding no preservatives or antioxidants.
This stability study validated the urine collection and storage
procedures we had already used in several epidemiologic studies in which we wished to measure EM in prospectively stored
urine samples and assess associations with subsequent cancer.
In epidemiologic studies of endogenous hormones and hormone
metabolism, urine samples offer some distinct advantages over
blood, including ease of biospecimen collection, potentially higher
participation rates, and the integration of exposure over time for
hormones with pulsatile, circadian, or menstrual cycle variability.

5. EM in blood
In 2007, we published the details of our LC–MS2 technique for
the simultaneous measurement of the absolute quantities of serum

EM [15]. In exploratory work, we had found, to our surprise, that all
15 EM we had detected in urine (Fig. 1) were also present in serum
in conjugated form, as sulfates or glucuronides, and that ﬁve of the
EM were present at quantiﬁable levels in unconjugated, or free,
form. Therefore, to accurately capture the concentration of total
endogenous estrogen in circulation and the concentrations of all
individual EM, we decided that for serum samples, we would do two
LC–MS2 analyses: one of total (conjugated + unconjugated) EM and
one of unconjugated EM. Unconjugated EM are measured by eliminating the enzymatic hydrolysis step in our method; total EM are
measured by including enzymatic hydrolysis; conjugated EM can
be calculated as the difference of the two analyses. To enhance accuracy, stable isotopically labeled EM standards are added to 1.0 mL
serum samples. Two 0.4 mL aliquots are created from each 1.0 mL
sample; only one of the two aliquots is hydroyzed. Both aliquots
are then extracted, derivatized, and analysed independently by
LC–MS2 .
Except for the change described above, where we measure both
total and unconjugated EM in each sample, our method for measuring all 15 EM concurrently in serum is similar to our method
for urinary EM. A total of 1.0 mL of serum is required to measure
both total and unconjugated EM. We currently use newer LC–MS2
systems for the serum analyses than the urine analyses, which
has resulted in a 5-fold increase in sensitivity. The lower level of
quantitation for each EM is 8 pg/mL serum (26.5–29.6 fmol/mL).
The level of detection, which is the “sensitivity” reported in the
literature for most steroid hormone assays, is ∼0.8 pg/mL serum
(<3 fmol/mL). Accuracy, based on recovery of a weighed amount of
unconjugated EM added to charcoal-stripped serum, is 91–113%.
Calibration curves are linear over a 103 -fold concentration range.
We are currently relying on six stable isotopically labeled standards
for the 15 EM: deuterated 2-hydroxyestradiol, 2-methoxyestradiol,
estriol, and 16-epiestriol and C-13 labeled estrone and estradiol.
We have not yet completed stability studies of individual EM
in serum during interim and long-term storage comparable to the
stability studies we performed for urinary EM. For serum collection
and storage, we use the protocol adopted by most epidemiologic
studies. Blood is kept at room temperature for no more than an
hour as it clots; the serum is collected by pipetting or decanting
after centrifugation. Once the serum is aliquotted, it is stored at 4 ◦ C
for no more than 12 h, and then transferred to −70 ◦ C for long-term
storage. No antioxidants or preservatives are used. It is generally
accepted that parent EM in serum or plasma are stable for up to 3
days during interim storage at 4 ◦ C, and for years during long-term
storage at −70 ◦ C. [23].
It is the extremely high sensitivity of our LC–MS2 assay—a
level of quantitation for each EM of 8 pg/mL serum and a level of
detection of ∼0.8 pg/mL serum—that enables us to measure circulating estrogens in postmenopausal women. Distinguishing serum
estradiol levels in the low postmenopausal range (<30 pg/mL;
<110 fmol/mL) is an important prognostic tool for common chronic
diseases of older women, speciﬁcally breast cancer, osteoporosis,
cardiovascular disease, and possibly cognitive dysfunction [24].
The ability to measure serum estradiol with high sensitivity and
speciﬁcity is particularly important in monitoring postmenopausal
women with hormone-dependent breast cancers who are receiving aromatase inhibitors. Suppression of estrogen production may
be inﬂuenced by non-compliance, hidden drug–drug interactions,
and genetically altered pharmacokinetics and can promote severe
bone loss [25]. Both indirect RIA methods, which include extraction
and/or chromatography, and direct RIA methods are not accurate
or sensitive enough to monitor serum estradiol at these low levels [25]. Bioassays that rely on recombinant yeast methods and
HeLa cells may be more sensitive than RIA but lack speciﬁcity and
convenience [25]. Gas chromatography/tandem mass spectrometry provides the needed speciﬁcity, sensitivity, and accuracy, but
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Fig. 4. Mean serum concentrations of unconjugated and conjugated forms of
15 estrogens and estrogen metabolites (EM) in eight postmenopausal women.
Serum concentrations, in fmol/mL, are plotted on a logarithmic scale. Conjugated forms of each EM are represented by the white section of the bar graph;
unconjugated forms are represented by the dark section of the bar graph. Total
concentration of each EM is represented by the entire bar graph. The standard error of the mean for total EM concentration is shown by the thatch
marks. Parent EM include estrone (E1 ) and estradiol (E2 ). 2-pathway EM include
2-hydroxyestrone (2-OHE1 ), 2-hydroxyestradiol (2-OHE2 ), 2-methoxyestrone (2MeOE1 ), 2-methoxyestradiol (2-MeOE2 ), and 2-hydroxyestrone-3-methyl ether
(3-MeOE1 ). 4-pathway EM include 4-hydroxyestrone (4-OHE1 ), 4-methoxyestrone
(4-MeOE1 ), and 4-methoxyestradiol (4-MeOE2 ). 16-pathway EM include 16␣hydroxyestrone (16␣-OHE1 ), estriol (E3 ), 17-epiestriol (17-epiE3 ), 16-ketoestradiol
(16-ketoE2 ), and 16-epiestriol (16-epiE3 ).

does not match the tight CV’s of our LC–MS2 method [25]. However, before any mass spectrometry method can be used in a clinical
environment to measure estradiol or other EM, detailed reference
protocols, calibration and validation requirements, and normative
values need to be developed [26].
We have completed a formal “proof of performance” for our
serum EM assay in eight postmenopausal women not on hormone
therapy. Two samples from each of the eight women were analysed
during each of four weeks. Laboratory CV’s were ≤5% for all total
and unconjugated EM, except for the two EM at the lowest concentrations: total 4-methoxyestradiol (CV = 6%) and total 17-epiestriol
(CV = 7%).
The descriptive data from this “proof of performance” were
intriguing, and are summarized in Fig. 4. This bar graph shows for
all 15 EM the mean serum concentrations, in fmol/mL, of conjugated, unconjugated, and total EM for the eight postmenopausal
women. Concentrations are shown on a logarithmic scale, and the
standard error of the mean for total EM is included. In general,
only circulating levels of estrone sulfate, estrone, and estradiol are
measured in epidemiologic and clinical studies. However, these
three EM are just a fraction of the physiologic complexity. In all
these women, all 15 EM we had previously characterized in urine
were also present in serum. The molar concentration in serum of
all 15 EM combined was generally more than three times that of
estrone sulfate, a biologically inactive estrogen which is thought to
be the estrogen reservoir and can be converted to estrone and estradiol in breast and other target tissues [27]. For each of the 15 EM,
the molar concentration of the conjugated form was substantially
higher than the molar concentration of the unconjugated form; in
fact, we detected only ﬁve unconjugated EM in circulation: estrone,
estradiol, estriol, 2-methoxyestrone, and 2-methoxyestradiol. We
could not detect any of the potentially mutagenic and genotoxic
catechol estrogens in circulation. Estradiol itself, considered the
biologically active form of estrogen and the predominant activator of estrogen receptor-mediated cellular processes, was more
abundant conjugated than unconjugated in most of the women.
Conjugated estradiol is not currently measured by the indirect or
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direct RIA assays for estradiol so its inﬂuence is generally not evaluated. Yet conjugated estradiol concentrations may be biologically
relevant since breast and other tissues contain sulfatases and glucuronidases that can generate biologically active estradiol from
conjugated estradiols in circulation. Evidence is increasing that sulfation/desulfation of EM represents a cyclic system important in the
regulation of biologically active estrogen in target tissue, while glucuronidation is the major pathway for estrogen excretion in urine
and bile [8,28].
We are currently expanding this “proof of performance” for
our serum EM assay to include premenopausal women and men.
While the laboratory CV’s will be interesting, the descriptive data
for total, conjugated, and unconjugated EM in circulation may well
be unique.
In trying to measure patterns of endogenous estrogen
metabolism, we have focused on 15 speciﬁc EM in conjugated and
unconjugated form, primarily the EM reported in early studies of
urinary EM. It is these EM for which we routinely include puriﬁed
standards in all our LC–MS2 runs. In the future, we will have the
opportunity to modify our method and utilize it to identify additional EM present in human urine and serum, including those due
to rare gene variants, environmental and lifestyle exposures, and
disease/treatment. We have not yet used the structure identiﬁcation properties of mass spectrometry to identify provocative peaks,
nor have we obtained a library of standards for additional EM that
might be present.

6. Comparing EM measurement by RIA or ELISA and by
LC–MS2
Absolute and relative EM concentrations are important for clinical decisions, as well as epidemiologic and experimental research
on hormonal carcinogenesis. RIA, EIA, and ELISA are routinely
used for measuring EM in blood and urine because of their efﬁciency, simplicity, and low cost. We wanted to compare these
widely accepted, commercially available methods with our new
LC–MS2 technique. In a population-based case-control study of
breast cancer in Asian–American women aged 20–55 years [29],
we had measured ﬁve EM in 12 h overnight urines collected
from 362 premenopausal and 168 postmenopausal controls. We
had chosen state-of-the-art methods and experienced laboratories
widely used by epidemiologists and clinicians. Estrone, estradiol,
and estriol were assayed at Nichols Institute (San Juan Capistrano, CA) with an indirect method involving enzymatic hydrolysis,
extraction, chromatography, and RIA [30]. 2-Hydroxyestrone and
16␣-hydroxyestrone were assayed at Strang Cancer Research
Laboratory (New York, NY) with a method involving enzymatic
hydrolysis and ELISA [31,32]. Recently we re-assayed the same
urines with our LC–MS2 method and compared the absolute and
relative results with those obtained earlier by RIA and ELISA [33].
For the premenopausal women, ranking subjects by RIA-based
measures of urinary estrone, estradiol, and estriol agreed quite well
with those obtained using LC–MS2 (rs > 0.9), while ranking subjects
by ELISA-based measures of urinary 2-hyroxyestrone and 16␣hydroxyestrone agreed reasonably well with LC–MS2 (rs = 0.8–0.9)
(Table 1). However, for the postmenopausal women, agreement
was noticeably reduced for all ﬁve EM (rs = 0.4–0.8).
Geometric mean concentrations (pmol/mg creatinine) of
estrone, estradiol, and estriol were 1.4–1.9 times higher by RIA
than LC–MS2 in premenopausal women, and 1.4–2.7 higher in
postmenopausal women (all p < 0.0001) (Table 1). Geometric mean
concentrations of 2-hydroxyestrone and 16␣-hydroxyestrone were
2.0–3.7 times higher by ELISA than LC–MS2 in premenopausal
women, and 2.7–11.8 times higher in postmenopausal women (all
p < 0.0001). These data suggested the RIA and ELISA assays had lim-
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Table 1
Comparison of urinary estrogen/estrogen metabolite (EM) measurement by RIA/ELISA and LC–MS2 : Spearman correlations and absolute concentrationsa .
EM

Premenopausal
luteal phase women
N = 264

Premenopausal
non-luteal phase women
N = 98

Postmenopausal
women
N = 168

Spearman correlations
2

RIA and LC–MS
Estrone
Estradiol
Estriol

0.94
0.91
0.94

0.96
0.95
0.94

0.79
0.63
0.73

ELISA and LC–MS2
2-Hydroxyestrone
16␣-Hydroxyestrone

0.81
0.86

0.89
0.89

0.37
0.62

Geometric mean concentrations (pmol/mg creatinine)
2

RIA or ELISA/LC–MS

RIA or ELISA/LC–MS2

RIA or ELISA/LC–MS2

RIA and LC–MS2
Estrone
Estradiol
Estriol

41.9/23.4
17.6/10.9
77.2/55.5

27.9/14.6
12.0/7.7
50.1/31.2

6.9/2.6
2.1/1.5
12.9/5.7

ELISA and LC–MS2
2-Hydroxyestrone
16␣-Hydroxyestrone

47.8/24.6
32.2/11.0

31.0/13.8
23.8/6.5

18.6/2.9
14.1/1.2

a
Subjects are Asian–American women, aged 20–55 years, selected as controls for a population-based case-control study of breast cancer [29]. 12 h overnight urines were
collected.

ited speciﬁcity and accuracy, and were detecting additional EM or
other steroids.
Based on the blinded quality control samples that we had
inserted for all the assays, laboratory CV’s for estrone, estradiol,
and estriol were ≤13% for RIA in premenopausal women, ≤18% for
RIA in postmenopausal women, and ≤5% for LC–MS2 in both premenopausal and postmenopausal women [33]. Laboratory CV’s for
2-hydroxyestrone and 16␣-hydroxyestrone were ≤14% for ELISA in
both premenopausal and postmenopausal women, ≤5% for LC–MS2
in premenopausal women, and ≤9% for LC–MS2 in postmenopausal
women. Thus, our results for reproducibility, as well as accuracy,
indicated that the widely used RIA and ELISA measures for EM
might be problematic, particularly at the low concentrations characteristic of postmenopausal women. Although this comparison of
state-of-the-art commercial assays with LC–MS2 was performed
with urine samples, it is plausible that in serum, a more complicated matrix, the commercial assays would perform even less well,
relative to LC–MS2 .
7. Future directions
We continue to optimize our EM LC–MS2 methods and reﬁne
them for the demands of large-scale epidemiologic research. We
are concentrating on three issues. (1) At present, we are using either
ﬁve or six stable isotopically labeled standards in our LC–MS2 methods for measuring 15 EM. In our laboratory, as soon as urines or
sera are defrosted for assay, we add the stable isotopically labeled
EM standards so that we can correct quantitatively for loss and
degradation. Ideally, stable isotope dilution requires a distinct isotopically labeled standard for each analyte so that we do not need
to extrapolate results from structurally similar, but not structurally
identical, compounds. We have now acquired 12 C-13 labelled standards and will be testing and incorporating them into our assays. (2)
Our current throughput per week on one LC–MS2 system is only 40
unknowns (which includes ∼4 blinded quality control samples) + 8
known quality control samples + 14 samples for two calibration
curves = 62 samples, only 58% of which are really unknowns. We
can receive “real-time” information each week on assay performance from the known quality control samples. Nonetheless, this

throughput means that it would require 25 weeks on each of two
LC–MS2 systems to measure both total and unconjugated EM concentrations in 1000 serum samples. Clearly, throughput needs to
be improved. We are currently testing some faster liquid chromatography systems potentially capable of increasing throughput
3-fold. (3) We have established standard operating procedures
for our methods and carefully described the optimized techniques in publications. However, to the extent that personnel may
need practical “hands-on” experience before they can successfully
implement the assays, we need to clarify, and possibly simplify, our
procedures.
While our LC–MS2 methods for measuring EM in serum and
urine are still being improved, they have been validated and are
robust and rapid and, therefore, appropriate for epidemiologic
work. We can assess total estrogen exposure, concentrations of
speciﬁc EM, and individual patterns of estrogen metabolism in
epidemiologic studies. In a population-based case-control study
of breast cancer in Asian–American migrants, we have explored
the relationship between urinary EM and Westernization in the
controls. Within these controls, Westernization predicts a 6-fold
gradient in risk of breast cancer, comparable to the historic international differences in breast cancer incidence between Asia and
the U.S. [29]. We have completed two nested case-control studies
of EM and breast cancer in large cohorts. The ﬁrst, in collaboration
with Drs. Hankinson and Eliassen, is of premenopausal breast cancer and utilizes prospectively stored urines from the Nurses’ Health
Study; the second is of postmenopausal breast cancer and utilizes
prospectively stored serum samples from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. We are
designing a nested case-control study of endometrial cancer and
circulating EM that will pool biospecimens from PLCO and other
cohorts. In collaboration with Drs. Kala Visvanathan and James
Yager at Johns Hopkins School of Medicine, we are testing methods
to measure EM in breast tissue and will examine the relationships
among conjugated and unconjugated EM in breast tissue, blood,
and urine.
Our LC–MS2 methods for measuring concurrently 15 EM in
serum and urine provide outstanding accuracy, precision, sensitivity, and speciﬁcity. However, the methods are still relatively
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labor-intensive and time consuming. We hope to apply our methods in important epidemiologic research where the quality of the
study design and potential impact of the results justify the use of
our methods. We anticipate that the application of our techniques
in epidemiologic research will inform further modiﬁcation of our
methods. Perfecting a method should not be an end in itself. Most
important, the results from our expanding portfolio of epidemiologic studies that have utilized these methods should help clarify
the role of endogenous estrogen exposure and estrogen metabolism
in the etiology of cancer.
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